Wedding Ulrich, Röhrig Bernd, Klippstein Almuth, Fricke Hans-Joerg, Sayer Herbert G, Höffken Klaus
Clinic for Internal Medicine II, Department of Hematology and Medical Oncology, Friedrich Schiller University, Erlanger Allee 101, 07747, Jena, Germany.
J Cancer Res Clin Oncol. 2006 Oct;132(10):665-71. doi: 10.1007/s00432-006-0115-7. Epub 2006 Jul 5.
Acute myeloid leukaemia (AML) is mainly affecting elderly patients. Elderly patients are increasingly affected by impairment of functional status (FS). FS is of prognostic relevance for survival in different tumours. Data for patients with AML are rare. Within a prospective trial we recruited patients with newly diagnosed AML and measured FS by two different methods: Karnofsky performance status (KPS) and instrumental activities of daily living (IADL). Sixty-three patients aged 19-85 years (median 61.1) were included. Twenty-three had prior myelodisplastic syndrome (MDS), 7 favourable, 17 unfavourable karyotype. Fifty received induction chemotherapy, 13 palliative chemotherapy. Median survival was 15.2 months (95% CI, 10.8-22.3) in all patients. Age, cytogenetic risk group, and impaired KPS and IADL significantly influenced median survival in univariate analysis. Impairment of IADL was the single most predictive variable. In multivariate analysis, impairment of IADL Score (HR:4.3, 95% CI 1.7-10.5, P = 0.001) and of KPS (HR:4.8, 95% CI 1.9-12.3, P = 0.001), and unfavourable cytogenetic risk group (HR:6.0, 95% CI 2.5-14.3, P < 0.001) significantly predicted median survival. In patients with AML, FS and not age is a major predictor of survival. The influence of FS is independent from cytogenetic risk group. IADL measurement adds information to KPS. The results have to be confirmed in a large sample of patients.
急性髓系白血病(AML)主要影响老年患者。老年患者越来越多地受到功能状态(FS)损害的影响。FS对不同肿瘤的生存具有预后相关性。AML患者的数据很少。在一项前瞻性试验中,我们招募了新诊断的AML患者,并通过两种不同方法测量FS:卡诺夫斯基表现状态(KPS)和日常生活工具性活动(IADL)。纳入了63例年龄在19 - 85岁(中位数61.1岁)的患者。23例曾患骨髓增生异常综合征(MDS),7例核型良好,17例核型不良。50例接受诱导化疗,13例接受姑息化疗。所有患者的中位生存期为15.2个月(95%CI,10.8 - 22.3)。在单因素分析中,年龄、细胞遗传学风险组以及KPS和IADL受损显著影响中位生存期。IADL受损是唯一最具预测性的变量。在多因素分析中,IADL评分受损(HR:4.3,95%CI 1.7 - 10.5,P = 0.001)、KPS受损(HR:4.8,95%CI 1.9 - 12.3,P = 0.001)以及不良细胞遗传学风险组(HR:6.0,95%CI 2.5 - 14.3,P < 0.001)显著预测中位生存期。在AML患者中,FS而非年龄是生存的主要预测因素。FS的影响独立于细胞遗传学风险组。IADL测量为KPS增加了信息。这些结果必须在大量患者样本中得到证实。